Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Processa Pharmaceuticals Inc (PCSA)

Processa Pharmaceuticals Inc (PCSA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,652
  • Shares Outstanding, K 15,838
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,430 K
  • 60-Month Beta -0.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.16
Trade PCSA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.26
  • Number of Estimates 1
  • High Estimate -0.26
  • Low Estimate -0.26
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.96 +4.73%
on 08/05/22
3.83 -18.95%
on 07/22/22
-0.20 (-6.06%)
since 07/08/22
3-Month
1.50 +106.67%
on 05/17/22
3.83 -18.95%
on 07/22/22
+1.04 (+50.49%)
since 05/09/22
52-Week
1.50 +106.67%
on 05/17/22
8.99 -65.52%
on 10/01/21
-3.08 (-49.84%)
since 08/09/21

Most Recent Stories

More News
Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST

HANOVER, MD, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing...

PCSA : 3.10 (-1.12%)
Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499

HANOVER, MD, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage...

PCSA : 3.10 (-1.12%)
Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499

HANOVER, MD, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage...

PCSA : 3.10 (-1.12%)
Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022

HANOVER, MD., July 12, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage...

PCSA : 3.10 (-1.12%)
Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

Amended Next Generation Capecitabine study has restarted which will elucidate timelines for de novo formation of DPDExpanded efforts for enrollment in...

PCSA : 3.10 (-1.12%)
Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)

Processa focuses on identifying the PCS6422 regimens to increase capecitabine potency while identifying the MTD of Next Generation Capecitabine The...

PCSA : 3.10 (-1.12%)
Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis

Study will advance understanding of proper dosing while providing data to assist in the design of the next study for this >$1B marketExpect top line...

PCSA : 3.10 (-1.12%)
Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update

Targeting Major Milestones 2022 HANOVER, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the...

PCSA : 3.10 (-1.12%)
Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST

HANOVER, MD, March 23, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing...

PCSA : 3.10 (-1.12%)
Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference

HANOVER, MD, March 10, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage...

PCSA : 3.10 (-1.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Processa Pharmaceuticals, Inc. is focused on the development of drug products which intended to improve the survival and/or quality of life for patients who have unmet medical need. Processa Pharmaceuticals Inc., formerly known as Heatwurx Inc., is based in HANOVER, United States.

See More

Key Turning Points

3rd Resistance Point 3.42
2nd Resistance Point 3.36
1st Resistance Point 3.23
Last Price 3.10
1st Support Level 3.04
2nd Support Level 2.97
3rd Support Level 2.84

See More

52-Week High 8.99
Fibonacci 61.8% 6.13
Fibonacci 50% 5.25
Fibonacci 38.2% 4.36
Last Price 3.10
52-Week Low 1.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar